Bibliography
- Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51
- Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
- Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:U74-81
- Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159-68
- Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-67
- Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000;148:387-96
- Betteridge DJ, Durrington PN, Fairhurst GJ, et al. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994;96:S45-54
- Lee JH, O'Keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83:324-32
- AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium). Prescribing information, July 2007
- Schuirmann DJ. Pharmacometrics: a comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80
- US Department of Health and Human Services. Guidance for industry: drug interaction studies – study design, data analysis, and implications for dosing and labeling. September 2006
- Warwick MJ, Dane AL, Raza A, et al. Single- and multiple-dose pharmacokinetics and safety of the new HMGCoA reductase inhibitor ZD4522. [abstract]. Atherosclerosis 2000;151:39
- McKenney JM, Swearingen D, Di SM, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-91
- Morelli G, DiSpirito M, Doyle RT, et al. Pharmacokinetic interaction study between prescription omega-3-acid ethyl esters (P-OM3) and atorvastatin in healthy subjects. Presented at American College of Clinical Pharmacy (ACCP), Denver, CO., 14-17 October 2007
- Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41
- Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-8
- Reliant Pharmaceuticals. Evaluation of efficacy and safety of Omacor, co-administered with atorvastatin, in subjects with hypertriglyceridemia. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00435045?term=nct00435045&rank=1 [Last accessed 16 October 2008]